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Background: The small bowel is one of the critical organs involved in gastrointestinal complications in cervical
cancer treated with postoperative intensity modulated radiotherapy. Even with modest doses of radiation therapy
(45-50Gy), the risk of severe injury from postoperative radiation therapy is between 5% and 15%. Up to now, a
predictive model of acute GI complications of the small bowel has been established with the aid of Quantitative
Analyses of Normal Tissue Effects in the Clinic. However, the correlation between dose-volume effect and chronic
GI complications of the small bowel has not been extensively investigated. In the article, the correlation has been
studied preliminarily.
Methods: This study analyzed 84 patients who underwent postoperative IMRT. The organ at risk that was
contoured was the small bowel loops. DVH parameters subjected to analysis included maximum and mean dose,
the volume of these organs receiving more than 30, 40, and 50 Gy (V30-50 volume) and the volume of V30-50 to
total volume (V30-50 ratio). Association between DVH parameters or clinical factors and the incidence of grade 1–2
chronic GI complications were evaluated.
Results: Body position and RT total dose are significantly associated with grade 1–2 chronic GI complications after
postoperative IMRT in early-stage cervical cancer patients. Maximum dose and V40 ratio of the small bowel loops
were significantly associated with chronic GI complications (P < 0.05). The optimal threshold were 5586 cGy
(maximum dose) and 28% (V40 ratio) of the small bowel loops.
Conclusions: Maximum dose and V40 ratio of the small bowel loops should be considered synthetically before
postoperative IMRT for early-stage cervical cancer.Background
Adjuvant whole pelvic radiation therapy (WPRT) after
radical hysterectomy reduces locoregional recurrence in
cervical cancer patients after surgery with adverse risk
factors [1,2]. Adjuvant concurrent chemoradiation ther-
apy has been shown to improve survival rates for high-
risk cervical cancer patients compared with adjuvant* Correspondence: wangping000001@163.com
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unless otherwise stated.WPRT alone [3,4]. Unfortunately, after hysterectomy,
small bowel tends to fall into the vacated space in the
true pelvis, increasing the amount of bowel treated to
high dose. The small bowel is one of the critical organs
involved in gastrointestinal (GI) complications. Even
with modest doses of radiation therapy (45-50Gy), the
risk of severe injury from postoperative radiation therapy
is between 5% and 15% [5,6]. Up to now, a predictive
model of acute GI complications of the small bowel has
been established with the aid of Quantitative Analyses of
Normal Tissue Effects in the Clinic (QUANTEC) [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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chronic GI complications of the small bowel in cervical
cancer treated with postoperative intensity modulated
radiotherapy (IMRT) has not been extensively investigated.
Since 2010, we have been using postoperative IMRT
for early-stage cervical cancer patients with adverse risk
factors. The purpose of the study reported here was to
evaluate dose-volume histogram (DVH) predictors for
the development of chronic GI complications in cervical




A total of 95 patients with cervical cancer received rad-
ical hysterectomy and postoperative IMRT at our insti-
tute between January 2010 and June 2012. Treatment
criteria for postoperative IMRT were indicated according
to Adjuvant Treatment in the NCCN Guidelines for cer-
vical cancer [1,8-11]. 11 of these patients were excluded
from the study: 3 who received extended-field radiation
therapy because of para-aortic lymph node metastases; 3
who received re-radiotherapy because of pelvic lymph
node metastases after the primary radiotherapy; and 5
who died because of distant metastases after postopera-
tive IMRT. The remaining 84 patients treated with radical
hysterectomy and postoperative IMRT were analyzed for
this study with a minimum follow-up period of 3 months.
All eligible patients were examined in a multidisciplinary
setting by surgery (Wang K), medical oncology (Huang D),
and radiation oncologist (Chen ZJ, Zhu L, and Zhang BL)
before being enrolled into the study. The study protocol
was in accordance with the ethical guidelines of the 1995
Declaration of Helsinki and was approved by the inde-
pendent ethics committees at Tianjin Medical University
Cancer Institute & Hospital, National Clinical Research
Center for Cancer (No. Ebc2014). The written informed
consent was obtained from all participants.
Radiation therapy and chemotherapy
Six patients were immobilized in the supine position in
an immobilization device in the early period, the others
were treated on a commercial bellyboard (KHLD-TJ-1200,
Beijing, China). The general set-up was to have the patient
lay prone on the bellyboard with the iliac crest aligned to
lie between the bellyboard hump and the inferior edge of
the opening. RT planning CT (Brilliance, Philips, Holland)
was performed with 5-mm slices with normal quiet
breathing and a full-bladder scan. The CT scan range was
from the upper edge of L3 to at least 7 cm below the bot-
tom of the obturator foramen. A commercial treatment
planning system (Pinnacle3 RTP, Philips, USA) was used
to design the radiation fields. The clinical target volume
(CTV) comprised a central vaginal CTV and a regionalnodal CTV. The former included the proximal vagina and
paravaginal tissues and the latter consisted of the common
iliac, external and internal iliac, and presacral lymph nodes.
CTV were contoured according to the consensus guidelines
of the Radiation Therapy Oncology Group (RTOG) 0418
and its atlas on the RTOG website [12]. The planning tar-
get volume (PTV) was generated by using 7-mm uniform
expansion of the CTV. RT was delivered using 6-megavolt
X rays from a linear accelerator (Varian 600C/D, USA). 75
patients (89%) received the whole RT dose as planned
(50.4 Gy), 9 patients (11%) received more than 50.4 Gy be-
cause of concurrent boost radiation therapy to positive pel-
vic lymph node region (60Gy). The prescribed RT doses
were administered in 28 fractions, 1.8-2.14 Gy/fraction,
5 fractions/week. The prescription dose is the isodose
which encompasses at least 97% of the vaginal PTV and
nodal PTV. No more than 20% of any PTV will receive >
110% of its prescribed dose. No more than 1% of any PTV
will receive < 93% of its prescribed dose. 41 patients were
given chemotherapy during the course of IMRT for 5 cycles,
of which 12 were given cisplatin (40 mg/m2) every week, 29
were given docetaxel (40 mg/m2) every week.Contouring and evaluation of normal structures
The small bowel loops were contoured on every slice,
including 2 cm above the PTV. It includes the volume
surrounding loops of small bowel out to the edge of the
peritoneum because the bowel may lie within this space
at any time throughout the course of treatment. The
large bowel, rectum and bladder were excluded from the
small bowel loops. DVH parameters subjected to ana-
lysis included maximum and mean dose to the small
bowel loops, V30-50 ratio and volume of this organ.
V30-50 volume means volume receiving more than
respective dose, and V30-50 ratio means volume receiv-
ing more than respective dose to total volume.Follow-up and evaluation of chronic GI complications
The patients were followed up by gynecologic and radi-
ation oncologists on an outpatient basis every month in
the first year, every 3 months in the second year, every
6 months in the third to the fifth year. We defined a
chronic complication as a GI event that occurred more
than 3 months after radiation therapy was started. The
severity of the GI complication was classified according
to the RTOG/European Organization for Research and
Treatment of Cancer Late Radiation Morbidity Score, as
follows: grade 0, no complications; grade 1, mild fibrosis,
mild cramping bowel, movement 5 times daily; grade 2,
moderate diarrhea and colic bowel, movement > 5 times
daily; grade 3, obstruction or bleeding, requiring surgery;
grade 4, necrosis, perforation fistula. Toxicity data in-
cluding the grade of GI complications were collected
Table 1 Patient and treatment characteristics
No. (%)
Age (y)




























Abbreviations: SCC = squamous cell carcinoma; BMI = body mass index;
RT = radiation therapy; SD = standard deviation.
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Statistical analysis
Associations between selected DVH parameters and the
incidence of grade 1–2 were evaluated. The relationships
between clinical or DVH parameters and the incidence
of chronic GI complications were analyzed with the
Mann–Whitney U test for quantitative variables and the
Fisher exact test for categorical variables. Multivariate
analysis using Cox regression models was performed to
identify risk factors associated with grade 1–2 chronic
GI complications. The mean DVH parameters for the
small bowel loops with and without GI complications
were compared by Mann–Whitney U test. Receiver op-
erating characteristics (ROC) curve analysis of each of
the DVH parameters with a P value of <0.05 in the uni-
variate analysis was performed to select the most rele-
vant threshold for prediction of grade 1–2 chronic GI
complication. The predictive value of each parameter
was evaluated based on the area under the ROC curve
(AUC). The AUC reflects the ability of the test to distin-
guish between patients with and without chronic GI tox-
icity. The optimal threshold for each DVH parameter
was defined as the point yielding the minimal value for
(1-sensitivity)2 + (1-specificity)2, which is the point on
the ROC curve closest to the upper left-hand corner
[13]. A P value of <0.05 or a 95% confidence interval not
encompassing 1 was considered to be statistically signifi-
cant. All statistical tests were 2-sided.
Results
The characteristics of the 84 patients are shown in
Table 1. The median follow-up period from the end of
radiation therapy was 16 months (range 4–36 months).
None of the patients experienced a local or distant re-
currence within 3 months. The Eastern Cooperative On-
cology Group performance status was 0–1 for all patients.
The median age of the patients was 47 years old (range
29–68 years old). The median total dose of docetaxel in
29 patients was 160 mg (range 40-280 mg), cisplatin in 12
patients was 160 mg (range 150-240 mg). 56 patients
(67%) had grade 0 chronic GI complications, 22 patients
(26%) had grade 1, 6 (7%) had grade 2, and no patient had
grade 3 or higher chronic GI complications.
The incidence of chronic GI complications was ana-
lyzed as a function of clinical factors. Because there were
few patients with a history of abdominopelvic surgery
among the study population, we did not analyze this fac-
tor. The results of univariate analyses are shown in
Table 2. Body position, RT total dose and concurrent
chemotherapy were significantly associated with grade
1–2 GI complications. Then multivariate analysis was
performed with these 3 potential risk factors of chronicGI complications. Of the 3 parameters, body position
and RT total dose emerged as independent predictors of
chronic GI complications (Table 3).
The mean DVH parameters of the small bowel loops
of patients with and without GI complications are shown
in Table 4. Patients with grade 1–2 chronic GI complica-
tions had significantly greater maximum dose and V40
ratio in the small bowel loops than did those without
chronic GI complications (P < 0.05).
ROC curve analysis was performed to select the most
relevant parameter to identify predictors of grade 1–2
chronic GI complications among DVH parameters with
a P value of <0.05 in the univariate analysis for the small
bowel loops (Table 5).
Table 2 Univariate analysis (Mann–Whitney U test and
Fisher exact test) for the development of grade 1–2
chronic GI complications
Grade 0 Grade 1-2
Variable No. No. P value
Age (y)
≤48 31 17 0.815
>48 25 11
T-stage
T1 42 21 1.000
T2 14 7
N-stage
N0 50 23 0.494
N1 6 5
Histology
SCC 53 27 1.000
Others 3 1
Smoking
None 51 28 0.164
Yes 5 0
Diabetes
None 52 25 0.681
Yes 4 3
BMI (kg/m2)
≤25 29 16 0.817
>25 27 12
Body position
Prone 56 22 0.001
Supine 0 6
RT total dose
50.4 Gy 54 21 0.005
>50.4 Gy 2 7
Concurrent chemotherapy
None 34 9 0.020
Yes 22 19
Chemotherapy regimens
Cisplatin 7 5 0.703
Docetaxel 15 14
Abbreviations: GI = gastrointestinal; SCC = squamous cell carcinoma;
BMI = body mass index; RT = radiation therapy.
Table 3 Multivariate analysis for the development of
grade 1–2 chronic GI complications
Variable HR (95% CI) P value
Body position 4.120 (1.513-11.217) 0.006
RT total dose 3.183 (1.312-7.720) 0.010
Concurrent chemotherapy 1.748 (0.742-4.120) 0.202
Abbreviations: GI = gastrointestinal; HR = hazard ratio; CI = confidence interval;
RT = radiation therapy.
Table 4 Comparison of mean DVH parameters of the
small bowel loops in patients with and without chronic
GI complications (Mann–Whitney U test)
Overall Grade 0 Grade 1-2 P value
Maximum dose (cGy ± SE)
5600 ± 257 5552 ± 207 5697 ± 318 0.042
Mean dose (cGy ± SE)
2918 ± 500 2838 ± 448 3077 ± 568 0.080
Mean ratio ± SE
V30 ratio 0.47 ± 0.14 0.46 ± 0.12 0.51 ± 0.17 0.301
V40 ratio 0.27 ± 0.12 0.24 ± 0.10 0.32 ± 0.15 0.011
V50 ratio 0.12 ± 0.08 0.11 ± 0.07 0.14 ± 0.08 0.134
Mean volume ± SE (ml)
Total volume 1008 ± 399 1041 ± 366 943 ± 458 0.261
V30 volume 460 ± 185 466 ± 173 448 ± 211 0.507
V40 volume 257 ± 125 248 ± 119 275 ± 136 0.423
V50 volume 107 ± 62 101 ± 52 119 ± 77 0.451
Abbreviations: DVH = dose-volume histogram; GI = gastrointestinal; SE = standard
error; V30-50 volume= volume receiving more than respective dose; V30-50
ratio = volume receiving more than respective dose to total volume.
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Many studies have introduced predictive factors poten-
tially associated with chronic GI complications after RT
for gynecologic malignancies [14-19]. Our study showed
that body position was significantly associated with
grade 1–2 GI complications in univariate and multivari-
ate analyses (P = 0.006, HR = 4.120). The percentage of
grade 1–2 toxicity in prone and supine position were28% and 100%, respectively. Cranmer-Sarqison reported
that the use of a bellyboard with IMRT provides excel-
lent small bowel sparing regardless of planning tech-
nique [20]. Hollenhorst also discribed that the mean
dose to the small bowel was 52.4% when the bellyboard
was used, as compared to a mean dose of 63.1% without
the bellyboard [21]. Collectively, these results suggest
that the use of a bellyboard with IMRT provides better
small bowel sparing.
Our study also showed that RT total dose had a sig-
nificant association with chronic grade 1–2 GI complica-
tions (P = 0.010, HR = 3.183). So it is important to select
the best DVH parameters to predict the possibility of
the incidences of chronic GI toxicity. There are two
points to be elaborated here about how to select the best
DVH parametes. First, IMRT patients had a lower rate
of chronic GI toxicity than that of WPRT patients
[22,23]. Our results also noted that the percentage of the
cervical cancer patients with grade 1, 2, and 3 toxicity
were as low as 26%, 7%, and 0%, respectively. For this
reason, the incidence of grade 1 and 2 chronic GI com-
plications were evaluated jointly. Second, the small
Table 5 ROC curve analysis for DVH parameters of the small bowel loops in relation to grade 1–2 chronic GI
complications
Optimal threshold
AUC 95% CI Value Sensitivity/specificity (%)
Maximum dose 0.637 0.503-0.770 5586 cGy 64.3/67.9
V40 ratio 0.670 0.540-0.800 0.28 67.9/57.1
Abbreviations: AUC = area under the ROC curve; CI = confidence interval; DVH = dose-volume histogram; GI = gastrointestinal; ROC = receive operating
characteristics; V30-50 volume = volume receiving more than respective dose; V30-50 ratio = volume receiving more than respective dose to total volume.
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guidelines of the Radiation Therapy Oncology Group
(RTOG) 0418 because they may lie within the volume
surrounding loops of small bowel out to the edge of the
peritoneum at any time throughout the course of treat-
ment [22]. Han et al. also emphasized that the dose dis-
tribution in the small bowel as observed on CT varies
significantly from week to week because of the interfrac-
tional variations of small bowel positions [7].
The results of univariate analyses showed that maximum
dose and V40 ratio of the small bowel loops had a signifi-
cant association with chronic GI complications (P < 0.05).
ROC curve analysis showed AUCs for the above 2 DVH
parameters were from 0.632 to 0.670, the optimal thresh-
old were 5586 cGy (maximum dose), 28% (V40 ratio) of
small bowel loops (Table 5). These findings suggest that
the two parameters may constitute a better predictor of
chronic GI complications. Similar results were found in
other studies. Isohashi reported that V40 of the small
bowel loops emerged as independent predictors of GI
complications after postoperative concurrent nedaplatin-
based chemoradiation therapy in early-stage cervical can-
cer patients [23]. Kavanagh noted that late small bowel
toxicity is likely related to maximum dose and/or volume
threshold parameters, qualitatively [22]. Interestingly, our
studies showed that V40 ratio of small bowel loops had a
significant association with chronic GI complications, but
total volume and V40 volume did not. The reason was
probably that V40 ratio is a more sensitive predictor and it
reflects the interplay between changing total volume and
V40 volume. For example, a thin patient’s total small bowel
volume is smaller than that of patients with normal body
weight. Although he has small V40 volume, his V40 ratio
will increase and he is more likely to suffer from chronic
GI toxicity.
The results of our univariate analyses showed concur-
rent chemotherapy was significantly associated with
grade 1–2 GI complications. The percentage of grade
1–2 toxicity in patients with and without concurrent
chemotherapy were 46% and 20%, respectively (P = 0.02).
But it was not an independent predictors of GI compli-
cations in multivariate analysis. Mundt also gained the
similar result, they reported that 53% gynecology pa-
tients who treated with IMRT received chemotherapy
(cisplatin 40 mg/m2/week), no significant correlationwas seen between the development of chronic GI tox-
icity and concurrent chemotherapy [24]. With regard to
chemotherapy regimens, Pu found that in high-risk early
stage cervical cancer patients, the incidence of late side
radiation effects was similar between docetaxel/cisplatin
group and single agent cisplatin group [25]. Our study
also got the same result, docetaxel group and cisplatin
group had no statistical difference in the incidence of
late small bowel complications.
Several previous studies reported that patients with
smoking, diabetes mellitus and lower BMI (<18.5 kg/m2)
were more likely to experience worse GI toxicities after
RT for gynecologic malignancies [15-19]. However, these
factors cannot be found to be associated with chronic GI
complications in our study. In general, the reasons are
as follows: only a few Chinese females were addicted to
smoking and suffered from diabetes mellitus at the mean
age of 48 [26,27]. Moreover, the value of BMI of the cer-
vical cancer patients in our studies was 25 ± 4 kg/m2,
higher than 18.5 kg/m2.Conclusions
We conclude that body position and RT total dose are
significantly associated with grade 1–2 GI complications
after postoperative IMRT in early-stage cervical cancer
patients. maximum dose and V40 ratio of small bowel
loops should be considered synthetically before radiation
therapy. The optimal threshold were 5586 cGy (max-
imum dose), 28% (V40 ratio) of the small bowel loops.
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